Ambenonium
A long-acting cholinesterase inhibitor that prevents the breakdown of acetylcholine at the neuromuscular junction, used to treat myasthenia gravis, an autoimmune disease causing muscle weakness. By maintaining higher levels of acetylcholine at nerve-muscle connections, it improves muscle strength and endurance in affected individuals.
Masse moléculaire
537,6000 g/mol
LogP
5,10
TPSA
58,20 Ų
Règle des 5 de Lipinski
Non conforme
Mécanisme d'action
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl
InChI
InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
Molecular Formula
C28H42Cl2N4O2+2
HBD / HBA
2 / 2
Liaisons Rotatives
14
Atomes Lourds
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A long-acting cholinesterase inhibitor that prevents the breakdown of acetylcholine at the neuromuscular junction, used to treat myasthenia gravis, an autoimmune disease causing muscle weakness. By maintaining higher levels of acetylcholine at nerve-muscle connections, it improves muscle strength and endurance in affected individuals.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Ambenonium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1652. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2131. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ambenonium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ambenonium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ambenonium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ambenonium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ambenonium"></drugfyi-drug>